Adjuvant and neoadjuvant therapy for breast cancer von Shien, Tadahiko, Iwata, Hiroji

Volltext

Clinical development of CDK4/6 inhibitor for breast cancer von Iwata, Hiroji

Volltext

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer von André, Fabrice, Ciruelos, Eva, Rubovszky, Gabor, Campone, Mario, Loibl, Sibylle, Rugo, Hope S, Iwata, Hiroji, Conte, Pierfranco, Mayer, Ingrid A, Kaufman, Bella, Yamashita, Toshinari, Lu, Yen-Shen, Inoue, Kenichi, Takahashi, Masato, Pápai, Zsuzsanna, Longin, Anne-Sophie, Mills, David, Wilke, Celine, Hirawat, Samit, Juric, Dejan

Volltext

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer von Turner, Nicholas C, Ro, Jungsil, André, Fabrice, Loi, Sherene, Verma, Sunil, Iwata, Hiroji, Harbeck, Nadia, Loibl, Sibylle, Huang Bartlett, Cynthia, Zhang, Ke, Giorgetti, Carla, Randolph, Sophia, Koehler, Maria, Cristofanilli, Massimo

Volltext

Current approach and future perspective for ductal carcinoma in situ of the breast von Kanbayashi, Chizuko, Iwata, Hiroji

Volltext

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer von Johnston, Stephen, Martin, Miguel, Di Leo, Angelo, Im, Seock-Ah, Awada, Ahmad, Forrester, Tammy, Frenzel, Martin, Hardebeck, Molly C., Cox, Joanne, Barriga, Susana, Toi, Masakazu, Iwata, Hiroji, Goetz, Matthew P.

Volltext

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer von Modi, Shanu, Saura, Cristina, Yamashita, Toshinari, Park, Yeon Hee, Kim, Sung-Bae, Tamura, Kenji, Andre, Fabrice, Iwata, Hiroji, Ito, Yoshinori, Tsurutani, Junji, Sohn, Joohyuk, Denduluri, Neelima, Perrin, Christophe, Aogi, Kenjiro, Tokunaga, Eriko, Im, Seock-Ah, Lee, Keun Seok, Hurvitz, Sara A, Cortes, Javier, Lee, Caleb, Chen, Shuquan, Zhang, Lin, Shahidi, Javad, Yver, Antoine, Krop, Ian

Volltext

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer von Cortes, Javier, Rugo, Hope S., Cescon, David W., Im, Seock-Ah, Yusof, Mastura M., Gallardo, Carlos, Lipatov, Oleg, Barrios, Carlos H., Perez-Garcia, Jose, Iwata, Hiroji, Masuda, Norikazu, Torregroza Otero, Marco, Gokmen, Erhan, Loi, Sherene, Guo, Zifang, Zhou, Xuan, Karantza, Vassiliki, Pan, Wilbur, Schmid, Peter

Volltext

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer von Schmid, Peter, Adams, Sylvia, Rugo, Hope S, Schneeweiss, Andreas, Barrios, Carlos H, Iwata, Hiroji, Diéras, Véronique, Hegg, Roberto, Im, Seock-Ah, Shaw Wright, Gail, Henschel, Volkmar, Molinero, Luciana, Chui, Stephen Y, Funke, Roel, Husain, Amreen, Winer, Eric P, Loi, Sherene, Emens, Leisha A

Volltext

Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management von Yoshimura, Akiyo, Imoto, Issei, Iwata, Hiroji

Volltext

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer von Turner, Nicholas C, Slamon, Dennis J, Ro, Jungsil, Bondarenko, Igor, Im, Seock-Ah, Masuda, Norikazu, Colleoni, Marco, DeMichele, Angela, Loi, Sherene, Verma, Sunil, Iwata, Hiroji, Harbeck, Nadia, Loibl, Sibylle, André, Fabrice, Puyana Theall, Kathy, Huang, Xin, Giorgetti, Carla, Huang Bartlett, Cynthia, Cristofanilli, Massimo

Volltext

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy von Masuda, Norikazu, Lee, Soo-Jung, Ohtani, Shoichiro, Im, Young-Hyuck, Lee, Eun-Sook, Yokota, Isao, Kuroi, Katsumasa, Im, Seock-Ah, Park, Byeong-Woo, Kim, Sung-Bae, Yanagita, Yasuhiro, Ohno, Shinji, Takao, Shintaro, Aogi, Kenjiro, Iwata, Hiroji, Jeong, Joon, Kim, Aeree, Park, Kyong-Hwa, Sasano, Hironobu, Ohashi, Yasuo, Toi, Masakazu

Volltext

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study von Emens, Leisha A, Molinero, Luciana, Loi, Sherene, Rugo, Hope S, Schneeweiss, Andreas, Diéras, Véronique, Iwata, Hiroji, Barrios, Carlos H, Nechaeva, Marina, Nguyen-Duc, Anh, Chui, Stephen Y, Husain, Amreen, Winer, Eric P, Adams, Sylvia, Schmid, Peter

Volltext

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer von Nozawa, Kazuki, Sawaki, Masataka, Iwata, Hiroji

Volltext

Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer von Noguchi, Emi, Shien, Tadahiko, Iwata, Hiroji

Volltext

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrin... von Cristofanilli, Massimo, Prof, Turner, Nicholas C, MD, Bondarenko, Igor, Prof, Ro, Jungsil, MD, Im, Seock-Ah, MD, Masuda, Norikazu, MD, Colleoni, Marco, MD, DeMichele, Angela, MD, Loi, Sherene, MD, Verma, Sunil, MD, Iwata, Hiroji, MD, Harbeck, Nadia, Prof, Zhang, Ke, PhD, Theall, Kathy Puyana, MD, Jiang, Yuqiu, PhD, Bartlett, Cynthia Huang, MD, Koehler, Maria, MD, Slamon, Dennis, Prof

Volltext

Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan von Sawaki, Masataka, Muramatsu, Yasuaki, Togo, Kanae, Iwata, Hiroji

Volltext

TNM classification of malignant tumors (Breast Cancer Study Group) von Sawaki, Masataka, Shien, Tadahiko, Iwata, Hiroji

Volltext

Management of breast cancer in older patients von Sawaki, Masataka, Shimomura, Akihiko, Shien, Tadahiko, Iwata, Hiroji

Volltext

The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status von Horisawa, Nanae, Adachi, Yayoi, Takatsuka, Daiki, Nozawa, Kazuki, Endo, Yuka, Ozaki, Yuri, Sugino, Kayoko, Kataoka, Ayumi, Kotani, Haruru, Yoshimura, Akiyo, Hattori, Masaya, Sawaki, Masataka, Iwata, Hiroji

Volltext